IgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.

These results show that an increase in TASK-3 expression levels, which could be modulated by PKC activation, reduces cell migration/invasion in breast cancer cells and suggest that modulation of TASK-3 expression may regulate metastasis of breast cancer cells.

Among 226 patients treated with icotinib, 71.7%(162/226) developed acquired resistance, and 28.3%(64/226) had primary resistance. Using the specimens at the baseline, there were 13(20.3%) patients with MET amplication, 8(12.5%) patients with BCL2L11 loss (BIM deletion polymorphism), 8(12.5%) patients with PTEN mutations, 6(9.4%) patients with MTOR mutations, 5(7.8%) patients with PIK3CA mutations, 3(4.7%) patients with FGFR3-TACC3 fusion, 2(3.1%) patients with EGFR T790M mutation, 2(3.1%) patients with HER2 amplication, 1(1.6%) patient with MYC amplication, and 16 (25.0%) patients with unknown status. Conclusions: MET amplication, BCL2L11 loss, PI3K-AKT-mTOR signaling pathway (PTEN, MTOR, PIK3CA mutations), FGFR3-TACC3, T790M, HER2 amplication or MYC amplication might contribute to molecular mechanisms of primary resistance to icotinib in EGFR Mþ NSCLC. Further investigations are warranted to overcome these primary resistances. Legal entity responsible for the study: Qu-Xia Zhang. Funding: Has not received any funding.

Aim/Background: The aim of this study was to assess the prognostic significance of the preoperative platelet count (PLT) and platelet-to-lymphocyte ratio (PLR) in patients with surgically resected non-small-cell lung cancer (NSCLC). Methods: We retrospectively reviewed 202 patients treated for NSCLC between January 2002 and December 2007. Preoperative PLT and PLR scores were calculated using data obtained at the time of admission. Patients were assigned a PLT-PLR score of 0, 1, or 2 based upon the presence of a high platelet count (> 450 × 10 3 /µL), an elevated PLR (> 160), or both. Results: Patients with a PLT-PLR score of 2 had a significantly lower median overall survival rate(OS)[12.715mo;95% confidence interval (CI) 1.215-24.215] when compared with patients with PLT-PLR scores of 1(52.238mo;95% CI 17.062-87.414) or 0( p < 0.001). Relapse-free survival (RFS) was also significantly decreased in patients with PLT-PLR scores of 2(10.107mo;95% CI 3.388-16.826) relative to patients with PLT-PLR scores of 1(27.214mo;95% CI 0-56.253) or 0(58.893mo; 95% CI 32.938-84.848, p < 0.001). Moreover, in subgroup analyses of patients with squamous cell carcinoma histology, OS( p < 0.001) and RFS( p < 0.001) were significantly worse in the high risk group(PLT-PLR score of 2) than in the low risk(PLT-PLR score of 1 or 0). Multivariate analysis suggested that age ≥ 65[hazard ratio(HR) 1.666; 95% CI 1.090-2.545; p = 0.018], advanced disease(HR 1.903; 95% CI 1.145-3.162;p = 0.013), and PLT-PLR score of 2(HR 3.787;95% CI 1.986-7.220;p < 0.001) were all independent prognostic factors for poor OS. Conclusions: Preoperative PLT-PLR scores can be useful for predicting disease prognosis in patients with surgically resected NSCLC. Further large prospective studies will be necessary to validate our findings. Disclosure: All authors have declared no conflicts of interest.